Efficacy of a standardized herbal preparation (Roidosanal®) in the treatment of hemorrhoids: A randomized, controlled, open-label multicentre study

Kapil Aggrawal, Naveen Satija1, Gita Dasgupta2, Partha Dasgupta3, Parul Nain4, Aditya R. Sahu5

General and Laparoscopy Surgery, Mohinder Hospital, Green Park, 1General and Laparoscopy Surgery, Batra Hospital, 2South End Clinic, Jain Mandir Complex, Masjid Modh, 3Former Drugs Controller General (I), Purvasa Apartments, Mayur Vihar, 4Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research, Sec 3 Pushp Vihar, 5Consultant, Choice Apartments, Mehrauli, New Delhi, India

ABSTRACT

Background: Catechins and epicatechins are monomers of naturally occurring proanthocyanidins, which have been reported with free radical scavenging, antioxidant, antiinflammatory, antiallergic, and vasodilatory properties. Plant parts rich in proanthocyanidins have been used for years in treatment of various ano-rectal diseases. This study compares the efficacy of two herbal preparations, Daflon® 500 mg and Roidosanal®, in ameliorating the signs and symptoms associated with hemorrhoids. Objective: To evaluate the safety and to compare the efficacy of a herbal preparation, Roidosanal® versus Daflon® 500 mg, on signs and symptoms of hemorrhoidal disease. Materials and Methods: In this pilot, active controlled, open-labeled multicentre study, 73 patients with proctoscopy proven hemorrhoids (Grade I to III) were randomly assigned to receive either Roidosanal® (Gr R; n = 37) or Daflon® 500 mg (Gr D; n = 36), for 15 days, at three centers in India. Assessment of hemorrhoidal symptoms was carried out in all patients at different time points. Intent-to-treat analysis was performed for both primary and secondary endpoints. Results: Baseline characteristics were comparable between the two groups. Both products were found to be equally effective in improving the ano-rectal conditions in Grade I and Grade II hemorrhoids; however, Roidosanal® demonstrated better efficacy in patients with Grade III hemorrhoids. Hemorrhoids associated symptoms like bleeding, pain, etc., improved in both groups, although intergroup comparisons were comparable. Conclusion: Both Roidosanal® and Daflon® 500 mg were equally effective in resolving signs and symptoms of hemorrhoids. Roidosanal® can be tried as a safe and effective treatment option for treatment of hemorrhoids. Further randomized, double-blind and large multicentre studies are recommended.

Key words: Bleeding, catechins, flavonoids, hemorrhoids, proctoscopy

INTRODUCTION

Hemorrhoids are one of the most common gastrointestinal disorders seen by general practitioners. It has been estimated that they can occur at any age and can affect both men and women.1 The natural evolution of hemorrhoids is benign in nature, but they tend to get worse over time, and therefore they should be treated as soon as it occurs. The term hemorrhoids (or piles) is used to describe the enlargement of the venous tissues of the anal region, which becomes inflamed or prolapsed.2

The anal canal consists of three fibrovascular cushions that are supported within the anal canal by a connective tissue framework, which is important in providing a watertight
Hemorrhoids are generally classified according to their position relative to the dentate line. External hemorrhoids originate below this line and become symptomatic only when thrombosed. Internal hemorrhoids arise above the dentate line and are marked by bleeding and protrusion. They can be further graded according to the degree of prolapse. Internal hemorrhoids that bleed but do not prolapse are designated as Grade I hemorrhoids; those that prolapse and reduce spontaneously (with or without bleeding) are second grade hemorrhoids; prolapsed hemorrhoids requiring manual reduction are Grade III hemorrhoids; and prolapsed hemorrhoids that cannot be reduced are Grade IV hemorrhoids.

Treatment options vary based on the degree and severity of symptoms. Management of hemorrhoids may be medical (prescribing high fiber diet, antimitoty agents, topical analgesics and corticosteroid creams for symptomatic relief, alternative/traditional medicine like oral flavonoids), nonoperative (sclerotherapy, cryotherapy, rubber band ligation, infrared photocogulation, etc.) or surgical (open, closed, or stapled hemorrhoidectomy). In many countries, 70-80% of the population use traditional medicine for primary health care. As per World Health Organization (WHO), 80% of about 4000 million inhabitants on this planet rely on plant medicines. Traditional healthcare systems are known to have different treatment regimens for management of hemorrhoids. Ayurveda is one of the traditional health care systems prevalent and practiced widely in India and other countries. Indian Regulations permit use of traditional medicine under proprietary ayurvedic medicine licenses. The preparations are approved by the state regulatory bodies and marketed. Several qualified ayurvedic physicians (~Vaidyas) practice traditional methods and use traditional medications for management of hemorrhoids. There are over half a million ayurvedic practitioners and over 800,000 registered traditional medicine practitioners in India.

Proanthocyanidins, present in various plant parts, comprising of catechins and epicatechins, have been reported with free radical scavenging, antioxidant, antiinflammatory, antiallergic, and vasodilatory activity. Proanthocyanidins have been shown to inhibit the enzymes hyaluronidase, elastase, and collagenase, which degrade connective tissue structures leading to increased vascular permeability. Moreover low compliance associated with treatments such as diet and lifestyle changes, hydrotherapy and mechanical compression therapy, renders oral therapy as an attractive option. Several studies have assessed the use of oral micronized, purified flavonoid fraction (MPFF) (Dafon® 500 mg) and is one of the most commonly used treatment option for Grade I and Grade II hemorrhoids.

On the basis of above considerations and probable mechanisms of action, we planned to use a marketed herbal preparation, Roidosanal® (as capsules; standardized to contain not less than 7% of total catechins and epicatechins). Both the above products possess similar active chemical entities (flavonoids) and therefore assumed to have a similar mechanism of action. We conducted a pilot scale, open-labeled, multicentre study to determine the safety of Roidosanal® capsules, and to compare its efficacy against Dafon® 500 mg, in patients with hemorrhoids.

**Materials and Methods**

**Study design**

This study was a multicentric, randomized, open labeled study conducted at three centers, namely, Mohinder Hospital, Batra Hospital and Research Center, and South End Clinic, in New Delhi from January 2009 to June 2010. The study was approved by an independent ethics committee. The study project was supported by Next Gen Pharma India Pvt. Ltd., New Delhi, India.

**Participants**

Patients of either gender, aged ≥18 years, with hemorrhoids confirmed by proctoscopy, visiting the recruitment centers were enrolled in the study. All patients had given signed informed consent before examination. Any patient presenting with anal fissures along with hemorrhoids was also recruited. Patients diagnosed with bleeding hemorrhoids and having no other abnormal vital signs and symptoms were included in the study. Pregnant and lactating women, alcoholics, and
patients currently using other antihemorrhoidal drugs or planning to undergo any surgical procedure for hemorrhoids were excluded from the study.

**Intervention**

The test product consisted of a processed herbal preparation, Roidosanal® (By Next Gen Pharma India Pvt. Ltd.) and it was compared with Daflon® 500 mg (By Serdia Pharmaceuticals (India) Pvt. Ltd.). Roidosanal® is a processed preparation from a mixture of four herbs, that is, gum-resin from Commiphora mukul (50%), gum-resin from Gardenia spp. (16.6%) and inflorescence from Tagetes erecta (16.7%), and Mesua ferrea (16.7%). It is formulated as capsules and standardized to contain not less than 7% of total catechins and epicatechins. The control preparation, Daflon® 500 mg contains micronized purified flavonoid extracts of rutaceae 500 mg, equivalent to 450 mg of diosmin, and 50 mg of hesperidine per tablet. Daflon® 500 mg is marketed in India for treatment of venous diseases, namely, chronic organic and functional venous deficiency of lower limbs, varicose veins, sequelae of phlebitis, hemorrhoids, etc.[23] Test product and comparator for the study were supplied by the sponsor. Patients were randomized at the initial consultation visit to receive either of the two treatments, Roidosanal® Caps (2 caps twice daily; Gr R) or Daflon® 500 mg Tabs (2 tablets daily; as per the recommended dosage in package insert of the product; Gr D), for 15 days. Compliance was ensured by project staff through regular phone calls and pill count at the end of treatment regimen. Patients were advised to restrict the amount of salt and spices in food. No laxatives or use of any other antihemorrhoidal drugs were allowed during the trial period.

**Adverse events**

All observed and reported adverse events regardless of treatment group or suspected causal relationship were recorded on the adverse events page of the case report form. Abnormal findings and clinically significant changes such as excessive pain and bleeding, abnormal local pain or itching were evaluated during clinical and physical examination.

**Randomization and allocation concealment**

Randomization was performed using permuted blocks of ten. The randomization list and numbered packing of intervention was carried out by a person not involved in the study. All the interventions and random numbers were packed in separate opaque envelopes. The interventions were dispensed in a serial fashion to the patients.

**Study assessments**

On visit 1, screening and randomization was done. This involved signed informed consent and enrolment of patients as per the inclusion and exclusion criteria. Demographics and medical history including previous history of hemorrhoids or any other chronic diseases was assessed. Proctologic examination was performed to assess the hemorrhoidal conditions, and then the patients were randomized. The investigational products were given to all patients for 15 days with instructions for administration. Each patient’s condition was assessed telephonically on the 8th day. On visit 2 (day 16) proctological examination was conducted again and it marked the end of treatment. However, the patients were followed-up, with visit 3 being the last visit, at the end of day 45. Tolerability of the interventions was evaluated subjectively by the investigator. Details of assessments done at each visit are explained below.

Proctoscopy was performed at baseline and end of treatment (16th day) by the same proctoscopy surgeon. Proctologic assessment was performed in the left-lateral position by inspection of the anal verge of the anal canal by using a proctoscope.[29,30] Parameters namely, grade (I, II, III, IV) and position of hemorrhoids (at one site, two sites or all three primary sites, i.e., 3’O clock, 7’O clock, 11’O clock position) were assessed. Hemoglobin and fecal occult blood tests were performed at baseline, 16th, and 45th day. Parameters namely, bleeding, itching, soiling, tenesmus, constipation, irritation after defecation per rectum were assessed qualitatively as Yes/No and frequency was measured quantitatively as none/week, 1-2 times/week or more than 2 times/week, at baseline, 8th, 16th, and 45th day of study. Anal pain was also recorded at the same time points using a linear visual analogue pain score (VAS) (range 0-10, 0 = no pain and 10 = the worst possible pain). However, the VAS score was regrouped as 1-3 = mild pain, 4-6 = moderate, and 7-10 = severe pain.[31]

**Endpoints**

The primary end points included change in “Grade” and “Position” of hemorrhoids, as measured using a proctoscope. Secondary end points included changes in hemorrhoidal signs and symptoms namely, bleeding, itching, pain, soiling, tenesmus, irritation after defecation, and constipation.

**Sample size calculation and statistical assessment**

Since this was the first randomized study using Roidosanal®, a pilot study was designed and therefore, sample size calculation was not done.

Mean ± standard deviation was computed for continuous variables. Frequencies and percentages were calculated for categorical data of all symptoms. Bivariate relationships between pair of variables were analyzed using Fisher’s exact test and Chi-square test. The analysis was subjected further
RESULTS

One hundred and twenty patients were screened, of whom 28 patients were excluded as they did not fulfill selection criteria and 19 patients voluntarily declined to be a part of the study. Out of 73 randomized patients, 37 patients (28:9 = Male: Female) received Roidosanal® (Gr R) and 36 patients (29:7 = M: F) received Daflon® 500 mg (Gr D) in a controlled fashion as shown in Figure 1. The mean age of patients in Gr R and Gr D was 36 and 32 years, respectively. A total of 73% in Gr R and 81% patients in Gr D had no history of pelvic surgery before the treatment. About 71% and 84% patients in Gr R and Gr D respectively, had no history of usage of medications for hemorrhoids. There were no significant differences in baseline characteristics for age, gender, past history of hemorrhoids, and duration of hemorrhoids and with regard to other ano-rectal disorders, grade of hemorrhoids, pain, bleeding, itching, soiling, irritation after defecation, constipation, tenesmus, and hemoglobin. Patients were allocated in a controlled fashion, keeping the randomization unbiased. Twenty-two (59.5%) patients in Gr R and 15 (41.7%) patients in Gr D completed the study. No serious adverse events were reported with either of the two treatment regimens, gastrointestinal upset was observed in three patients in Gr D.

Response in ano-rectal conditions

The distribution of patients at baseline between the two groups in terms of ano-rectal conditions were comparable (P = 0.299; Table 1). Both Roidosanal® (P < 0.001) and Daflon® 500 mg (P = 0.027) significantly improved the ano-rectal conditions [Table 1].

Severity of hemorrhoids (grade and position of hemorrhoids)

The percentage distribution of all patients with regard to site and grade is shown in Table 1. Roidosanal® and Daflon® 500 mg were equally effective in patients with Grade I and Grade II hemorrhoids. Roidosanal® showed better efficacy and faster resolution of signs and symptoms in patients with Grade III hemorrhoids. A significantly higher number of patients with Grade III hemorrhoids improved in Gr R as compared with Gr D (six patients in Gr R vs 0 patients in Gr D; P value < 0.05; Binomial test; not shown in Table 1). This is an important aspect, as Grade III hemorrhoids, unlike Grade I and II hemorrhoids, do not usually present spontaneous improvement of the symptoms.

Symptoms associated with hemorrhoids

Bleeding

Intergroup analysis revealed that both Daflon® 500 mg and Roidosanal® were comparable in decreasing the extent and

---

**Figure 1: Flow of patients**
frequency of bleeding associated with hemorrhoids at all visits. Intragroup analysis showed that there were lesser no.
of patients in Gr R with complaints of bleeding as compared with patients in Gr D on Day 8 ($P = 0.004$ vs $P = 0.102$,
Figure 2). The number of patients complaining of bleeding decreased in both groups on Days 16 and 45, but did not reach statistical significance. The frequency of bleeding [Table 3] decreased significantly in both groups on Day 8 ($P = 0.050$ and $P = 0.046$ in Gr R and Gr D respectively) as compared with baseline, however, the changes on Days 16 and 45 did not reach statistical significance. This could be due to a smaller sample size owing to a pilot trial design.

**Pain**

There was significant decrease in severity and frequency of ano-rectal pain in both groups on Days 8, 16, and 45 [Figure 3 and Table 3]. The intergroup analysis was comparable as both products demonstrated similar efficacy in relieving severity and frequency of pain on 8th, 16th, and 45th day [Figure 3 and Table 3].

**Itching**

Both Roidosanal® and Daflon® 500 mg were equally effective in relieving the itching symptom and reducing its frequency [Tables 2 and 3]. The relief from itching was observed as early as on the 8th day, lasting till the end of study. There was no significant difference in the efficacy of both products in relieving symptoms of itching, when compared against each other at all visits [Tables 2 and 3].

**Soiling**

Eight (21.6%) patients in Gr R and five (13.9%) patients in Gr D complained of soiling at baseline. However, both the products were able to provide relief from soiling immediately, and lasting till the end of treatment [Tables 2 and 3].

**Tenesmus**

Intergroup analysis did not yield any significant difference; both Roidosanal® and Daflon® 500 mg were equally effective in relieving tenesmus symptom. Both the treatments

---

**Table 1: Ano-rectal conditions of patients at baseline and after treatment on day 16**

| Parameters                          | Ano-rectal condition         | Gr R, n (%) | P value | Gr D, n (%) | P value |
|-------------------------------------|-----------------------------|------------|---------|------------|---------|
|                                     | Baseline*                   | After treatment* |         | Baseline* | After treatment* |         |
| Ano-rectal condition                |                             |            |         |            |         |
| No active hemorrhoids               | 0 (0)                       | 3 (8.1)    | <0.001* | 0 (0)      | 1 (2.8)  | 0.027* ns* |
| Internal hemorrhoids                | 18 (48.6)                   | 25 (67.6)  |         | 21 (58.4)  | 27 (75)  |         |
| Hemorrhoids with fissures           | 1 (2.8)                     | 2 (5.4)    |         | 3 (8.3)    | 4 (11.1) |         |
| Internal hemorrhoids and fissures   | 18 (48.6)                   | 7 (18.9)   |         | 12 (33.3)  | 4 (11.1) |         |
| Site of hemorrhoids                 |                             |            |         |            |         |
| One site                            | 17 (53.1)                   | 19 (59.4)  | 0.120*  | 13 (43.4)  | 16 (53.3) | <0.001* ns* |
| Two sites                           | 11 (34.4)                   | 11 (34.4)  |         | 11 (36.6)  | 9 (30)   |         |
| All three sites                     | 12 (41.5)                   | 2 (6.2)    |         | 6 (20)     | 5 (16.7) |         |
| Grades of hemorrhoids               |                             |            |         |            |         |
| Grade I                             | 6 (18.7)                    | 8 (25)     | 0.023*  | 7 (23.3)   | 10 (33.3) | <0.001* ns* |
| Grade II                            | 15 (45.9)                   | 39 (59.4)  |         | 16 (53.4)  | 12 (40)  |         |
| Grade III                           | 11 (34.4)                   | 5 (15.6)   |         | 7 (23.3)   | 8 (26.7) |         |

*Beginning of treatment (Day 1); *End of treatment (Day 16); ^P values for comparison between groups after treatment; *Pearson Chi-square test; ns=Not significant.

Distribution of patients at baseline: Gr. R vs Gr D (P = 0.299, Pearson Chi-square test)

---

**Figure 2:** Distribution of patients with bleeding symptom at baseline and at follow-ups. Within group differences as depicted above were compared using Pearson chi-square test. Between group differences (Roidosanal® vs Daflon®) at all visits were comparable (Pearson chi-square test; Day 0, $P = 0.922$; Day 8, $P = 0.737$; Day 16, $P = 0.526$; Day 45, $P = 0.418$)

**Figure 3:** Distribution of patients with pain symptom at baseline and at follow-ups. Within group differences as depicted above were compared using Pearson chi-square test. Between group differences (Roidosanal® vs Daflon®) at all visits were comparable (Pearson chi-square test; Day 0, $P = 0.577$; Day 8, $P = 0.408$; Day 16, $P = 0.765$; Day 45, $P = 0.751$)
Intergroup analysis revealed a similar efficacy of both treatments [Table 2]. Intragroup analysis demonstrated that patients in both groups were relieved of the irritation after defecation symptom on Days 8, 16, and 45 in a significant manner as compared with baseline [Table 2].

**Irritation after defecation**

Table 2: Hemorrhoidal symptoms at baseline and outcome on days 8, 16 and 45

| Presence of symptoms | Gr R, n (%) | Gr D, n (%) | P value* | P value* | P value* |
|----------------------|------------|------------|----------|----------|----------|
| Itching              |            |            |          |          |          |
| Yes                  | 20 (54.1)  | 12 (32.4)  | 17 (47.2) | 10 (27.8) | 9 (25.0) |
| No                   | 17 (45.9)  | 25 (67.6)  | 19 (52.8) | 26 (72.2) | 24 (66.7) |
| P value              | 0.001a     | 0.001a     | <0.001a   | <0.001a   | 0.004a   |
| Soiling              |            |            |          |          |          |
| Yes                  | 8 (21.6)   | 4 (10.8)   | 5 (13.9)  | 1 (2.8)   | 0 (0)    |
| No                   | 29 (78.4)  | 33 (89.2)  | 31 (86.1) | 35 (97.2) | 36 (100) |
| P value              | <0.001a    | <0.001a    | 0.012a    | n.d.      | n.d.     |
| Tenesmus             |            |            |          |          |          |
| Yes                  | 16 (43.2)  | 7 (18.9)   | 16 (44.4) | 12 (33.3) | 7 (19.4) |
| No                   | 21 (56.8)  | 30 (81.3)  | 20 (55.6) | 24 (66.7) | 29 (80.6) |
| P value              | 0.012a     | 0.006b     | 0.001a    | 0.109b    | 0.018b   |
| Irritation after defecation |        |            |          |          |          |
| Yes                  | 26 (70.3)  | 13 (35.1)  | 16 (44.4) | 12 (33.3) | 7 (19.4) |
| No                   | 11 (29.7)  | 24 (64.9)  | 20 (55.6) | 26 (72.2) | 27 (75)  |
| P value              | 0.04a      | 0.006b     | 0.001a    | 0.001a    | 0.005a   |
| Constipation         |            |            |          |          |          |
| Yes                  | 26 (70.3)  | 15 (40.5)  | 26 (72.2) | 17 (47.2) | 10 (27.8) |
| No                   | 11 (29.7)  | 22 (59.5)  | 10 (27.8) | 19 (52.8) | 26 (72.2) |
| P value              | 0.001a     | 0.004a     | <0.001a   | 0.020a    | 0.009a   |

**Table 3: Frequency of hemorrhoidal symptoms at baseline and outcome on days 8, 16, and 45**

| Frequency of symptoms | Baseline | Day 8 | Day 16 | Day 45 | P value* | P value* | P value* |
|-----------------------|----------|-------|--------|--------|----------|----------|----------|
| Bleeding              |          |       |        |        |          |          |          |
| None                  | 15 (40.6)| 28 (75.7)| 25 (67.6)| 28 (75.7)|          |          |          |
| 1-2 times/week        | 6 (16.2)| 7 (18.9)| 4 (10.8)| 6 (16.2)| 9 (25.0) | 4 (11.1) | 1 (2.8)  |
| >2 times/week         | 16 (43.2)| 2 (5.4)| 3 (8.1)| 12 (33.3)| 6 (16.7) | 3 (8.3)  | 3 (8.3)  |
| P value               | 0.050a   | 0.180b | 0.174a | 0.046a | 0.061b  | 0.150a   |          |
| Pain                  |          |       |        |        |          |          |          |
| None                  | 9 (24.3)| 17 (45.9)| 23 (62.2)| 24 (64.9)| 15 (41.7) | 26 (72.2) | 32 (88.9) |
| 1-2 times/week        | 6 (16.2)| 12 (32.4)| 6 (16.2)| 8 (21.6)| 12 (33.3) | 6 (16.7) | 3 (8.3)  |
| >2 times/week         | 22 (59.5)| 8 (21.6)| 8 (21.6)| 5 (13.5)| 18 (50.0) | 8 (22.2) | 7 (19.4) |
| P value               | 0.001a   | 0.007b | 0.074a | <0.001a| 0.020b  | 0.009a   |          |
| Itching               |          |       |        |        |          |          |          |
| None                  | 17 (45.9)| 25 (67.6)| 26 (70.3)| 26 (70.3)| 19 (52.8) | 26 (72.2) | 25 (69.4) |
| 1-2 times/week        | 6 (16.2)| 5 (13.5)| 7 (18.9)| 6 (16.2)| 7 (19.4) | 5 (13.9) | 8 (22.2) |
| >2 times/week         | 14 (37.8)| 7 (18.9)| 4 (10.8)| 5 (13.5)| 10 (27.8) | 5 (13.9) | 3 (8.3)  |
| P value               | 0.004a   | 0.023b | 0.037d | <0.001a| 0.001b  | 0.002d   |          |
| Soiling               |          |       |        |        |          |          |          |
| None                  | 29 (78.4)| 33 (89.2)| 34 (91.9)| 35 (94.6)| 32 (86.1) | 35 (97.2) | 36 (100) |
| 1-2 times/week        | 3 (8.2)| 2 (5.4)| 2 (5.4)| 5 (14.3)| 4 (11.1) | 1 (2.8)  | 0 (0)    |
| >2 times/week         | 5 (13.4)| 2 (5.4)| 1 (2.7)| 0 (0)  | 1 (2.8)  | 0 (0)    | 0 (0)    |
| P value               | <0.001a  | 0.004b | 0.016d | 0.006e  | n.d.     | n.d.     |          |

Aggrawal, et al.: Roidosanal® for the treatment of hemorrhoids

improved the symptoms of tenesmus significantly after 8 days of treatment [Table 2].

**Constipation**

Patients with history of constipation in Gr R were relieved significantly on 8th (P = 0.001), 16th (P < 0.004), and 45th Day (P < 0.025) as compared with baseline.
Patients in Gr D showed significant relief only on the 8th day ($P = 0.042$; Table 2). The relief with Roidosanal® was prompt, achieved within 8 days of treatment, and sustained till the end of treatment and follow-up visit.

**Diarrhea**

Two (5.4%) patients in Gr R and 1 (2.8%) patient in Gr D complained of diarrheal symptoms at baseline ($P = 0.999$). Diarrheal symptoms improved in two patients (one in Gr R and one in Gr D) after treatment.

**Hemoglobin level**

Mean hemoglobin level at baseline was found to be 12.52 and 12.54 g/dl in Gr R and Gr D, respectively. Hemoglobin levels slightly improved after treatment (12.69 g/dl in Gr R and 12.70 g/dl in Gr D); however, the change between the groups or within group was not significant.

**DISCUSSION**

Though there is anecdotal evidence demonstrating the use of herbal medicines containing bioflavonoids in ano-rectal diseases, scientific studies in this field are grossly inadequate. Herbal products are attracting attention in developed countries too, as an alternative to high cost modern drugs and associated side effects.

A comparative, open label trial in different grades of hemorrhoids, confirmed by proctoscopy was conducted in a total of 73 patients at three centers in urban and semi-urban areas catering to varied population of socioeconomic status and educational levels. The selected patients were randomly allocated to two groups, namely, a group taking processed herbal preparation (Roidosanal®) or a popularly prescribed preparation (Daflon® 500 mg) available in Indian market. The characteristic signs and symptoms of hemorrhoids were scored for both groups at baseline, 8th, 16th, and on 45th day of treatment.

Therapeutic objectives in treatment of piles include shrinkage of piles mass, subsiding inflammation and preventing infection in the anal region, preventing bleeding from the rectum, relieving itching in the anal region, and relieving constipation as well. Of all the above, reduction in inflammation, bleeding, pain, anal itching, soiling, and constipation. The study also demonstrates the importance of traditional medicine in the normal routine of a patient with hemorrhoids unless there is an absolute need for surgical intervention.

**Limitations of the study** included a pilot design (no sample size calculation), open label design, and no central laboratory for biochemistry tests or proctoscopy.

**CONCLUSION**

Roidosanal® was found to be equally effective as Daflon® 500 mg in improving ano-rectal conditions and associated signs and symptoms of hemorrhoids. There were no major adverse events associated with the use of either product. Treatment of patients with Grade I to Grade III hemorrhoids with preparations like Roidosanal® or Daflon® 500 mg would be beneficial and can be looked for. Further large and double-blind trials with proper statistical methods need to be conducted to confirm the results.

**ACKNOWLEDGMENT**

The authors express their gratitude to Next Gen Pharma India (New Delhi) for the financial support and for providing the study medications used in the study.

**REFERENCES**

1. Agbo SP. Surgical management of hemorrhoids. J Surg Tech Case Rep 2011;3:68-75.
2. Thomson WH. The nature of hemorrhoids. Br J Surg 1975;62:542-52.
3. Lacerda-Filho A, Silva RG. Stapled hemorrhoidectomy: Present status. Arq Gastroenterol 2005;42:191-4.
4. Nisar PJ, Scholefield JH. Managing hemorrhoids. BMJ 2003;327:847-51.
5. Lohsiriwat V. Hemorrhoids: From basic pathophysiology to clinical management. World J Gastroenterol 2012;18:2009-17.
6. Shanimugam V, Thaha MA, Rabindranath KS, Campbell KL, Steele RJ, Loudon MA. Rubber band ligation versus excisional hemorrhoidectomy for hemorrhoids. Cochrane Database Syst Rev 2012;20:CD005034.
7. Johansson HO. uu.diva-portal.org [homepage on the internet]. Hemorrhoids: aspects of symptoms and results after surgery. Dissertation, Uppsala Universitet. Available from: http://uu.diva-portal.org/smash/get/diva2:167326/FULLTEXT01.pdf. [Last accessed on 2013 Nov 07].
8. Madoff RD, Fleshman JW. American Gastroenterological Association technical review on the diagnosis and treatment of hemorrhoids. Gastroenterology 2004;126:1463-73.
9. Thomson JP, Leicester RJ, Smith LE. Hemorrhoids. In: Henny MM, Swash M, editors. Coloproctology and the pelvic floor. 2nd ed. Oxford: Butterworth-Heinemann; 2004. p. 272-93.
10. Lorenzo-Rivero S. Hemorrhoids: Diagnosis and current
management. Am Surg 2009;75:635-42.
11. Banov L Jr, Knoepp LF Jr, Erdman LH, Alia RT. Management of hemorrhoidal disease. J Soc Med Assoc 1985;81:398-401.
12. Farnsworth NR, Akerele O, Bingel AS, Soejarto DD, Guo Z. Medicinal plants in therapy. Bull World Health Organ 1985;63:965-81.
13. Indian medicine.nic.in [homepage on the internet] Available from: http://indianmedicine.nic.in/showfile.asp?id=44 [Last accessed on 2013 Oct 28].
14. MacKay D. Hemorrhoids and varicose veins: A review of treatment options. Altern Med Rev 2001;6:126-40.
15. Murray M, Pizzorno J. Procyanidolic oligomers. In: Murray M, Pizzorno J, editors. The Textbook of Natural Medicine. 2nd ed. London: Churchill Livingstone; 1999. p. 899-902.
16. Frankel EN, Kanner J, German JB, Parks E, Kinsella JE. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet 1993;341:454-7.
17. Chen ZY, Chan PT, Ho KY, Fung KP, Wang J. Antioxidant activity of natural flavonoids is governed by number and location of their aromatic hydroxyl groups. Chem Phys Lipids 1993;79:157-63.
18. Nuttall SL, Kendall MJ, Bombardelli E, Morazzoni P. An evaluation of the antioxidant activity of a standardized grape seed extract, Leucoselect. J Clin Pharm Ther 1998;23:385-9.
19. Bagchi D, Krohn RL, Bagchi M, Tran MX, Stohs SJ. Oxygen free radical scavenging abilities of vitamins C and E, and a grape seed proanthocyanidins extract in vitro. Res Commun Mol Pathol Pharmacol 1997;95:179-89.
20. Bagchi D, Garg A, Krohn RL, Bagchi M, Bagchi DJ, Balmoori J, et al. Protective effects of grape seed proanthocyanidins and selected antioxidants against TPA-induced hepatic and brain lipid peroxidation and DNA fragmentation, and peritoneal macrophage activation in mice. Gen Pharmacol 1998;30:771-6.
21. Tixier JM, Godeau G, Robert AM, Hornebeck W. Evidence by in vivo and in vitro studies that binding of pycnogenols to elastin affects its rate of degradation by elastases. Biochem Pharmacol 1984;33:3933-9.
22. Masquelier J. Procyanidolic oligomers (Leucocyanidins) [translated from French]. Parfums Cosmetiques Aromes.